{"classes":[{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","lowerLimit":"NA","spread":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG002","spread":"NA","value":"100.8"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG003","spread":"NA","value":"134.9"}]}],"title":"Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.5","value":"295.0"},{"groupId":"OG001","spread":"96.7","value":"490.8"},{"groupId":"OG002","spread":"82.0","value":"373.5"},{"groupId":"OG003","spread":"99.9","value":"676.7"}]}],"title":"Children (age>=2 & <12yr; n=10; n=16; n=8; n=6)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.1","value":"320.8"},{"groupId":"OG001","spread":"35.0","value":"488.1"},{"groupId":"OG002","spread":"76.2","value":"787.0"},{"groupId":"OG003","spread":"56.6","value":"526.1"}]}],"title":"Adolescents (age>=12 & <18yr; n=9; n=8; n=9; n=2)"},{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG001","spread":"NA","value":"367.2"},{"comment":"No participants in this age group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Above 18 years (n=0; n=1; n=0; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.2","value":"307.0"},{"groupId":"OG001","spread":"88.9","value":"484.3"},{"groupId":"OG002","spread":"89.6","value":"504.1"},{"groupId":"OG003","spread":"103.9","value":"534.9"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-T) is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with plasma samples available. Each participant could have more than 1 plasma profiles sampled, depending on the number of times the dose of dasatinib was escalated. n=number of PK parameters included.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"ng.h/mL"}